US HB878 | 2017-2018 | 115th Congress
Status
Spectrum: Partisan Bill (Republican 86-3-1)
Status: Introduced on February 6 2017 - 25% progression, died in committee
Action: 2017-03-02 - Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Pending: House Subcommittee on Crime, Terrorism, Homeland Security, And Investigations Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 6 2017 - 25% progression, died in committee
Action: 2017-03-02 - Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Pending: House Subcommittee on Crime, Terrorism, Homeland Security, And Investigations Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Right to Try Act of 2017 This bill requires the federal government to allow unrestricted manufacturing, distribution, prescribing, and dispensing of experimental drugs, biological products, and medical devices that are: (1) intended to treat a patient who has been diagnosed with a terminal illness, and (2) authorized by state law. The federal government must allow unrestricted possession and use of such treatments by patients certified by a physician as having exhausted all other treatment options. A manufacturer, distributor, prescriber, dispenser, possessor, or user of such a treatment has no liability regarding the treatment. The outcome of manufacture, distribution, prescribing, dispensing, possession, or use of such a treatment may not be used by a federal agency to adversely impact review or approval of the treatment. The treatment must: (1) have successfully completed a phase 1 (initial, small scale) clinical trial; (2) remain under investigation in a clinical trial approved by the Food and Drug Administration; and (3) not be approved, licensed, or cleared for sale under the Federal Food, Drug, or Cosmetic Act or the Public Health Service Act.
Title
Right to Try Act of 2017
Sponsors
History
| Date | Chamber | Action |
|---|---|---|
| 2017-03-02 | House | Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations. |
| 2017-03-02 | House | Referred to the Subcommittee on the Constitution and Civil Justice. |
| 2017-02-10 | House | Referred to the Subcommittee on Health. |
| 2017-02-06 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2017-02-06 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2017-02-06 | House | Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. |
| 2017-02-06 | House | Introduced in House |
Same As/Similar To
HB2368 (Related) 2017-06-07 - Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
SB204 (Related) 2018-05-30 - Became Public Law No: 115-176.
HR905 (Similar To) 2018-05-22 - Motion to reconsider laid on the table Agreed to without objection.
SB204 (Related) 2018-05-30 - Became Public Law No: 115-176.
HR905 (Similar To) 2018-05-22 - Motion to reconsider laid on the table Agreed to without objection.
Subjects
Civil actions and liability
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Health technology, devices, supplies
Licensing and registrations
Long-term, rehabilitative, and terminal care
Prescription drugs
Product safety and quality
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Health technology, devices, supplies
Licensing and registrations
Long-term, rehabilitative, and terminal care
Prescription drugs
Product safety and quality
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/115th-congress/house-bill/878/all-info |
| Text | https://www.congress.gov/115/bills/hr878/BILLS-115hr878ih.pdf |
